Agios Pharmaceuticals Acquires Alnylam’s siRNA Blood Disease Program
Agios Pharmaceuticals Inc. announced its acquisition of Alnylam Pharmaceuticals, Inc.’s siRNA blood disease program targeting TMPRSS6, a gene that makes protein. According to data captured in the LevinPro HC database, this transaction marks the 105th Biotechnology acquisition in 2023. Alnylam is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002. According to its most recent financial report, the company achieved net product revenues of $894 million during FY 2022. Agios is the pioneering leader in pyruvate kinase (PK) activation... Read More »
Cybin Acquires Small Pharma
Cybin, Inc. announced on August 28 its acquisition of Small Pharma, Inc. a London-based biotechnology company progressing a pipeline of short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Small Pharma has a portfolio of clinical-stage DMT-based assets, SPL026 and SPL028. Small Pharma was granted an Innovation Passport designation for SPL026 from the U.K. Medicines and Healthcare products Regulatory Agency and has a pipeline of proprietary preclinical assets. Cybin is a biopharmaceutical company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Headquartered in Toronto and founded in... Read More »
Cell Microsystems Acquires Fluxion Biosciences
Durham, North Carolina-based Cell Microsystems announced its acquisition of Fluxion Biosciences. According to data captured in the LevinPro HC database, this acquisition represents the 102nd Biotechnology transaction of 2023, and 19th in the third quarter. Fluxion delivers advanced solutions that automate complex cell-based and cell-free assays. Products include ERASE-Seq for NGS analysis of cancer from a “liquid biopsy” blood sample, IsoFlux for circulating tumor cell analysis, BioFlux for functional analysis of cellular interactions and the IonFlux automated patch clamp system. Cell Microsystems provides pioneering solutions for cell biology research, and... Read More »
CervoMed Inc. Closes Acquisition of EIP Pharma
CervoMed Inc. (formerly known as Diffusion Pharmaceuticals) announced on August 17 that it closed its previously announced acquisition of EIP Pharma, Inc. The combined company will trade on the Nasdaq Capital Market under the ticker symbol, “CRVO”. EIP Pharma is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of debilitating neurodegenerative diseases. It is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). CervoMed is a biopharmaceutical company that has historically focused on developing novel therapies that enhance... Read More »
Swiftmerge Acquisition Corp. Takes HDL Therapeutics Public in $400 Million Transaction
On August 11, Swiftmerge Acquisition Corp., a West Vancouver-based special purpose acquisition company, announced that it was taking HDL Therapeutics Inc. public through a merger. HDL Therapeutics is a biotech innovator, focused on developing first-in-class treatments for intractable cardiovascular and neurovascular diseases using the company’s proprietary technology platform. The holders of the outstanding HDL Therapeutics preferred stock and common stock will receive a combination of cash and equity in Swiftmerge totaling $400 million. The business combination values the combined company at approximately $480 million. Upon closing of the merger, Swiftmerge will change its... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
